An interventional study of Step count goal and Actigraph watch in Pregnancy Complications, Mental Health Issue and Depression, Anxiety, sponsored by Stanford University. Enrolling by invitation at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-15.
Sponsored by Stanford University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 127 studies in Pregnancy Complications with a site in United States — 39 open to participants now, 47 under way, 1 of them phase 3. Pregnancy Complications · United States.
Among the 127 studies in Pregnancy Complications with a site in United States, this one is the 36th largest by planned enrollment of the 66 interventional ones that give a count, is one of 17 that started in 2025, is one of 45 with no phase, reaches primary completion later than 14 of the 46 other live ones, and was the 100th registered.
411 studies on the registry are indexed under Pregnancy Complications; 111 are open to participants now.
Browse Pregnancy Complications studies →39 of the 127 studies in Pregnancy Complications with a site in United States are open now. Recruiting first, the newest first:
Duke University · Sites in United States
Ages 0 days–9 mo
University of Florida · Sites in United States
Ages 15–49 · Women only
Medicines360 · Sites in United States
Ages 18–99 · Women only · Healthy volunteers
Kenneth Moise MD · Sites in United States
Ages 18–45 · Women only
Michigan State University · Sites in United States
Ages 18+ · Women only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 90 Pregnancy Complications studies recruiting now, 43 (48%) set no upper age limit and 44 (49%) stop at 75 or younger; 22 take children under 18; 35 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
127 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 9 · Phase 3 8 · Phase 4 6
First in 1995; this study’s year is marked. 17 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 88 is below the median of 144 across 205 interventional studies indexed under Pregnancy Complications.
Median enrollment 96 across the 66 interventional studies, 477 across the 61 observational. Of the 69 that completed or were terminated, 19 (28%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 127 have an industry lead sponsor. The 10 most frequent:
Stanford University is the lead sponsor of 2,171 studies on the registry; 425 are open to participants now.
Of its 268 completed or terminated interventional studies of FDA-regulated products, 207 (77%) have results posted.
Stanford University has 7 studies filed under Pregnancy Complications — fewer than ten, so there is no comparison to draw.
20 of the studies in Pregnancy Complications with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05552053Phase 3Cedars-Sinai Medical CenterResources, Inspiration, Support and Empowerment (RISE) for Black Pregnant Women | 2026-12-31 |
| NCT04544462Genomic Prediction Inc.ANXA5 M2 Haplotyping in IVF Patients and Embryos | 2026-11 |
| NCT06529042Mount Sinai Hospital, CanadaSCRIPT: Sickle Cell Risk in Pregnancy Tool | 2026-12 |
| NCT06026969Children's National Research InstitutePregnancy and Early Neurodevelopmental Outcomes Following In Utero Lyme Disease Exposure | 2026-12 |
| NCT06790043Albany Medical CollegeImpact of Patient Selected Visual Art in the Hospital Room During Antepartum Admission on Hospital Satisfaction Scores and Patient Experience | 2026-12 |
Add all 20 to your calendar (.ics) → With an account.
Among the 127 studies in Pregnancy Complications with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This randomized control trial will evaluate whether a physical activity intervention can improve mental health and biologic markers of stress in pregnant people with depressive or anxiety symptoms. The study will enroll participants if they are presenting for prenatal care at Stanford Children's Health Obstetrics Clinic with a singleton gestation.
Study Design This will be a randomized, parallel group, unblinded, single site superiority trial evaluating the impact of a physical activity intervention on reducing symptoms in people with known or screen-positivity for depression or anxiety during pregnancy. Participants will be randomized to a step count intervention versus usual care. Adherence will be monitored via Actigraph Link GT9X accelerometer watches.
Primary outcome: The primary outcome will be the mean within-person change in EPDS score between Time 2 (randomization) and Time 3 (37 weeks).
Secondary outcomes: Secondary outcomes will include additional psychobiologic measures, pregnancy complications, SMM events, and neonatal outcomes as shown below:
Covariates: Demographic, clinical, and socioeconomic covariates of interest will be collected from participants. These variables will be ascertained via patient report (e.g. highest level of education, annual income, number of jobs worked, self-identified race and ethnicity, engagement in mental health treatments) and via chart abstraction (e.g. medical comorbidities, substance use, body mass index, neonatal birthweight and Apgar score). If covariates are unbalanced between groups, results from Aim 1 will be used to prioritize which covariates should be accounted for in adjusted models.
Analyses. The primary analysis will compare the difference in mean within person EPDS score change between Time 2 and Time 3 in the study across the control and intervention groups. If the mean EPDS differences are normally distributed, analysis will be conducted using independent t-tests. If not, analysis will be conducted using nonparametric tests such as Wilcoxon rank-sum tests. If any demographic or clinical characteristic emerges unbalanced between the randomization groups, an additional analysis will be conducted adjusting for this as a potential confounder as long as assumptions are met for linear regression techniques. Secondary outcomes will be compared using t-tests for normally distributed continuous variables, Wilcoxon rank sum tests for nonparametric continuous variables, and chi square tests for categorical variables. Changes in secondary questionnaire outcomes over time (such as differences in STAI, EPDS) will be compared using the differences in an individual's scores. Mean maternal leukocyte telomere and hair cortisol differences between Time 2 and Time 3 will be compared across groups as continuous variables.
Missing data: Based on our prior longitudinal studies with similar populations, we expect completion rates of >70%, with little item-level missing data. We will conduct intent-to-treat analyses for Aim 2 based on all available data. Missing data will not be imputed for primary outcomes. Given the exploratory nature of the biologic outcomes and small sample size, missing values will also not be imputed. Multiple imputation will be used for missing covariates deemed necessary to adjust for in statistical modeling. Patterns of missingness will be examined as needed.
Power: Using EPDS as the continuous outcome variable compared between independent control and experimental subjects with a 1:1 allocation ratio, standard deviation of 4.89 in the control group, and true difference in mean EPDS scores of 4.00, we will need 25 subjects per group using an independent t-test to reject the null hypothesis that the population means of the groups are equal with power of 0.80 and Type 1 error probability of 0.05. To account for 20% loss to follow up, stratification, and block randomization in blocks of 2 and 4, we will enroll 44 per group for a total N=88 participants.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will wear an Actigraph accelerometer watch, but not be given a step count goal, between 20 and 36 weeks of gestation.
Device: Actigraph watch
Participants will be given a daily step count goal of 8,000 steps per day based on the Actigraph watch, between 20 and 36 weeks of gestation. If they are not at goal, a step-up protocol will be designed for each participant and reviewed with a study team member every 2 weeks.
Behavioral: Step count goal · Device: Actigraph watch
The step count goal will be discussed at the beginning of the study, and participants will be able to see their step count on the Actigraph watch to facilitate achieving this goal. All participants will receive weekly reminders that are tailored for their intervention arm. Intervention group participants will also receive a step count diary with motivational ideas of how to obtain step goals, which will be reviewed with a study team member every 2 weeks.
Both groups will wear the watch. Adherence will be assessed via step counts from accelerometer watch.
Also known as: Actigraph GT9X Link Accelerometer
Change in Edinburgh Postpartum Depression Scale (EPDS) Score
The mean within person change in EPDS score between randomization and the end of the study will be compared between the 2 arms. The EPDS is a 10-question validated measure with a score range of 0-30 for depression and/or anxiety screening in pregnancy that has been translated into many languages. A score of \>=10 has been shown to be consistent with depressive symptoms.
Time frame: Randomization around 20 weeks gestation and end of study (around 37 weeks gestation).
Change in EPDS Anxiety Subscale Score
The mean within person change in Edinburgh Postpartum Depression Anxiety Subscale score between randomization and the end of the study will be compared between the 2 arms. The three-question anxiety subscale on the EPDS (EPDS 3A) has a score range between 0-9, and a score \>=5 has been shown to be consistent with anxiety symptoms.
Time frame: Randomization around 20 weeks gestation and end of study (around 37 weeks)
Change in State-Trait Anxiety Inventory (STAI) Score
Mean within person change in STAI score between randomization and the end of the study will be compared between the 2 arms. The STAI is 40 questions, and the score ranges from 40 to 160. A STAI score \>=80 has been shown to be consistent with anxiety symptoms.
Time frame: Randomization around 20 weeks gestation and end of study (around 37 weeks)
Change in leukocyte telomere length
Maternal leukocyte telomere length will be measured from saliva samples and analyzed via quantitative PCR. Mean within-person change in leukocyte telomere length will be compared between the two arms.
Time frame: Randomization around 20 weeks and end of study (around 37 weeks)
Change in hair cortisol level
Maternal hair cortisol level will be measured from consecutive segments of hair strands. Mean within-person change in hair cortisol level will be compared between the two arms.
Time frame: Randomization around 20 weeks and end of study (around 37 weeks)
Frequency of pregnancy complications
Frequency of pregnancy complications including hypertensive disorders, diabetes, fetal growth restriction, placental abruption, preterm birth, or stillbirth will be abstracted from the medical record
Time frame: 6 weeks postpartum
Frequency of neonatal complications
Frequency of neonatal complications including NICU admission, 5-minute Apgar \<7, low birthweight, need for mechanical ventilation, or neonatal demise will be abstracted from the medical record
Time frame: 6 weeks postpartum
Neonatal leukocyte telomere length
Salivary
Time frame: Day of life 1
Plan to share: No
No publications or documents are linked to this record.
Started Jan 2025 (actual). Primary completion is estimated for Jan 2027, 23 months after the start.
Of 119 non-industry interventional studies with no phase under Pregnancy Complications, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 48. This study's planned 23 months is below that.
Counting every sponsor, half of 119 studies reached it within 26 months; a quarter within 12 and three quarters within 48.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.